Fosun International LTD Has Cut Mylan N V (MYL) Position By $1.38 Million; Northrim Bancorp Has 1.29 Sentiment

Mylan N.V. (NASDAQ:MYL) Logo

Fosun International Ltd decreased Mylan N V (MYL) stake by 31.42% reported in 2018Q4 SEC filing. Fosun International Ltd sold 51,209 shares as Mylan N V (MYL)’s stock declined 17.51%. The Fosun International Ltd holds 111,791 shares with $3.06 million value, down from 163,000 last quarter. Mylan N V now has $14.49 billion valuation. The stock increased 0.32% or $0.09 during the last trading session, reaching $28.09. About 9.70 million shares traded or 75.86% up from the average. Mylan N.V. (NASDAQ:MYL) has declined 30.99% since March 17, 2018 and is downtrending. It has underperformed by 35.36% the S&P500. Some Historical MYL News: 17/05/2018 – FDA names drugmakers likely blocking access to branded drug samples; 11/04/2018 – MYLAN SAYS WILL BE SUBMITTING AN INVESTIGATIONAL NEW DRUG APPLICATION TO U.S. FDA FOR MELOXICAM; 25/04/2018 – GLAXO 1Q ADVAIR REV. GBP566M, EST. GBP586.6M; 27/04/2018 – TEVA PHARMACEUTICAL INDUSTRIES LTD – NO NEW OR UNEXPECTED ADVERSE EVENTS EMERGED IN PATIENTS RECEIVING COPAXONE 40 MG/ML FOR UP TO 7 YEARS; 03/05/2018 – COHERUS BIOSCIENCES – RE-SUBMISSION OF BLA FOR CHS-1701, A PEGFILGRASTIM (NEULASTA┬«) BIOSIMILAR CANDIDATE, TO U.S. FDA UNDER 351(K) PATHWAY; 08/05/2018 – MYLAN MYL.O SAYS INFORMED FDA A FEW MONTHS AGO THAT IT HAD INTERMITTENT EPIPEN SUPPLY CONSTRAINTS DUE TO MANUFACTURING DELAYS FROM PFIZER; 11/04/2018 – Mylan Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira┬« (adalimumab); 13/04/2018 – Mylan seeks deal for German Merck’s consumer products unit; 09/04/2018 – Recordati Completes Acquisition of International Rights to Cystagon (Cysteamine Bitartrate) From Mylan; 09/05/2018 – Mylan Faces EpiPen Shortage as Slowing Sales Trip Up Its Results

Northrim Bancorp Inc (NRIM) investors sentiment decreased to 1.29 in 2018 Q4. It’s down -0.35, from 1.64 in 2018Q3. The ratio fall, as 36 funds increased and opened new stock positions, while 28 trimmed and sold stock positions in Northrim Bancorp Inc. The funds in our database now hold: 4.63 million shares, down from 4.67 million shares in 2018Q3. Also, the number of funds holding Northrim Bancorp Inc in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 26 Increased: 27 New Position: 9.

Investors sentiment decreased to 0.33 in Q4 2018. Its down 1.17, from 1.5 in 2018Q3. It is negative, as 1 investors sold MYL shares while 2 reduced holdings. 1 funds opened positions while 0 raised stakes. 129,903 shares or 38.96% less from 212,833 shares in 2018Q3 were reported. Gulf Int Savings Bank (Uk) Limited holds 115,438 shares. Gemmer Asset Mngmt Lc has invested 0% in Mylan N.V. (NASDAQ:MYL).

Among 15 analysts covering Mylan (NASDAQ:MYL), 11 have Buy rating, 0 Sell and 4 Hold. Therefore 73% are positive. Mylan had 20 analyst reports since October 5, 2018 according to SRatingsIntel. The stock of Mylan N.V. (NASDAQ:MYL) earned “Neutral” rating by Mizuho on Friday, October 5. The firm has “Buy” rating given on Tuesday, November 6 by Citigroup. BTIG Research maintained Mylan N.V. (NASDAQ:MYL) rating on Wednesday, February 27. BTIG Research has “Buy” rating and $35 target. The firm has “Buy” rating by BMO Capital Markets given on Wednesday, February 27. The firm has “Buy” rating given on Wednesday, February 27 by Raymond James. RBC Capital Markets maintained Mylan N.V. (NASDAQ:MYL) rating on Wednesday, February 27. RBC Capital Markets has “Buy” rating and $45 target. J.P. Morgan maintained it with “Buy” rating and $39 target in Wednesday, February 27 report. Cantor Fitzgerald maintained Mylan N.V. (NASDAQ:MYL) rating on Tuesday, February 26. Cantor Fitzgerald has “Hold” rating and $41 target. The firm earned “Buy” rating on Wednesday, February 27 by Wells Fargo. Mizuho maintained the stock with “Hold” rating in Wednesday, February 27 report.

Fosun International Ltd increased Cymabay Therapeutics Inc (NASDAQ:CBAY) stake by 328,289 shares to 792,096 valued at $6.20M in 2018Q4. It also upped Unitedhealth Group Inc (NYSE:UNH) stake by 4,290 shares and now owns 11,290 shares. Marinus Pharmaceuticals Inc (NASDAQ:MRNS) was raised too.

More notable recent Mylan N.V. (NASDAQ:MYL) news were published by: Nasdaq.com which released: “Notable Thursday Option Activity: MYL, JNJ, BMY – Nasdaq” on March 14, 2019, also Nasdaq.com with their article: “Mylan (MYL): Big Drop Sets Up A Contrarian Value Play – Nasdaq” published on February 28, 2019, Nasdaq.com published: “Mylan (MYL) to Report Q4 Earnings: What’s in the Offing? – Nasdaq” on February 20, 2019. More interesting news about Mylan N.V. (NASDAQ:MYL) were released by: Nasdaq.com and their article: “Mylan (MYL) Q4 Earnings & Revenues Miss Estimates, Stock Down – Nasdaq” published on February 27, 2019 as well as Seekingalpha.com‘s news article titled: “Why Mylan Shares Will Rebound This Year – Seeking Alpha” with publication date: March 05, 2019.

Analysts await Mylan N.V. (NASDAQ:MYL) to report earnings on May, 8. They expect $0.90 earnings per share, down 6.25% or $0.06 from last year’s $0.96 per share. MYL’s profit will be $464.35 million for 7.80 P/E if the $0.90 EPS becomes a reality. After $1.30 actual earnings per share reported by Mylan N.V. for the previous quarter, Wall Street now forecasts -30.77% negative EPS growth.

The stock increased 0.14% or $0.05 during the last trading session, reaching $37.07. About 25,812 shares traded or 53.10% up from the average. Northrim BanCorp, Inc. (NRIM) has risen 13.46% since March 17, 2018 and is uptrending. It has outperformed by 9.09% the S&P500. Some Historical NRIM News: 30/04/2018 – Northrim Bancorp 1Q EPS 58c; 21/04/2018 DJ Northrim BanCorp Inc, Inst Holders, 1Q 2018 (NRIM); 25/05/2018 – Northrim BanCorp, Inc. Declares Quarterly Cash Dividend of $0.24 per Share

More notable recent Northrim BanCorp, Inc. (NASDAQ:NRIM) news were published by: Seekingalpha.com which released: “Northrim BanCorp declares $0.30 dividend – Seeking Alpha” on March 01, 2019, also Nasdaq.com with their article: “Northrim BanCorp Inc (NRIM) Ex-Dividend Date Scheduled for March 13, 2019 – Nasdaq” published on March 12, 2019, Globenewswire.com published: “Northrim BanCorp, Inc. Raises Quarterly Cash Dividend 12.5% to $0.27 per Share – GlobeNewswire” on August 24, 2018. More interesting news about Northrim BanCorp, Inc. (NASDAQ:NRIM) were released by: Globenewswire.com and their article: “Northrim BanCorp, Inc. Appoints Aaron M. Schutt to its Board of Directors – GlobeNewswire” published on December 04, 2018 as well as Seekingalpha.com‘s news article titled: “43 Upcoming Dividend Increases – Are You Kidding Me? – Seeking Alpha” with publication date: March 08, 2019.

Pacific Ridge Capital Partners Llc holds 0.82% of its portfolio in Northrim BanCorp, Inc. for 74,410 shares. Private Capital Management Llc owns 89,176 shares or 0.49% of their US portfolio. Moreover, Dalton Greiner Hartman Maher & Co has 0.21% invested in the company for 86,601 shares. The Ontario – Canada-based Hillsdale Investment Management Inc. has invested 0.19% in the stock. Walthausen & Co. Llc, a New York-based fund reported 40,991 shares.

Since January 1, 0001, it had 5 insider purchases, and 0 selling transactions for $96,220 activity.

Northrim BanCorp, Inc. operates as bank holding firm for Northrim Bank that provides commercial banking services and products to businesses and professional individuals primarily in Alaska. The company has market cap of $255.04 million. The firm operates in two divisions, Community Banking and Home Mortgage Lending. It has a 12.96 P/E ratio. It offers various deposit products, including noninterest-bearing checking accounts and interest-bearing time deposits, checking accounts, and savings accounts, as well as money market deposit accounts, certificates of deposit, and courier noncash deposits.

Northrim BanCorp, Inc. (NASDAQ:NRIM) Institutional Positions Chart